{"filing":{"accession_number":"0001193125-26-387890","cik":"0001806952","ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"d278670d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312526387890/d278670d8k.htm"},"events":[{"id":32661,"run_id":30022,"accession_number":"0001193125-26-387890","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure centers on completion of a technology transfer for LYL273 to Lyell's LyFE Manufacturing Facility following FDA review, combined with an updated timeline for the Phase 1/2 clinical trial (now expecting data and End-of-Phase 1 meeting in 2027). This is a material operational and clinical milestone—successful manufacturing transfer and FDA clearance of an improved process—but does not fit the specific categories of earnings release, M\u0026A activity, material impairment, or other named event types. The operational nature of the manufacturing milestone and clinical trial progress update makes operational_other the most appropriate classification.","company_name":"Lyell Immunopharma, Inc.","ticker":"LYEL","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35888,"accession_number":"0001193125-26-387890","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on completion of a technology transfer for LYL273 to Lyell's LyFE Manufacturing Facility following FDA review, combined with an updated timeline for the Phase 1/2 clinical trial (now expecting data and End-of-Phase 1 meeting in 2027). This is a material operational and clinical milestone—successful manufacturing transfer and FDA clearance of an improved process—but does not fit the specific categories of earnings release, M\u0026A activity, material impairment, or other named event types. The operational nature of the manufacturing milestone and clinical trial progress update makes operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:19:00.991174+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35888,"accession_number":"0001193125-26-387890","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on completion of a technology transfer for LYL273 to Lyell's LyFE Manufacturing Facility following FDA review, combined with an updated timeline for the Phase 1/2 clinical trial (now expecting data and End-of-Phase 1 meeting in 2027). This is a material operational and clinical milestone—successful manufacturing transfer and FDA clearance of an improved process—but does not fit the specific categories of earnings release, M\u0026A activity, material impairment, or other named event types. The operational nature of the manufacturing milestone and clinical trial progress update makes operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:19:00.991174+00:00","company_name":"Lyell Immunopharma, Inc.","ticker":"LYEL","filing_date":"2026-09-10"}]}